Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients

Holló G., Hommer A., Antón López A., Ropo A.

2014
Journal of Ocular Pharmacology and Therapeutics

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Department of Ophthalmology, Semmelweis University, Maria St. 39, Budapest 1085, Hungary; Krankenanstalt Sanatorium Hera, Vienna, Austria; Department of Glaucoma, Institut Catala de Retina-Inici, Barcelona, Spain; Santen Oy, Clinical Research and Medical Affairs, Helsinki, Finland

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications